港交所(00388.HK)投资广州期货交易所7%股权 涉资2.1亿人币
港交所(00388.HK)宣布,投资新设立的广州期货交易所7%股权,投资涉及金额2.1亿元人民币,为境外机构首次获准入股中国内地期货交易所,突显港交所连接中国与世界、支持内地期货市场进一步国际化的决心。
港交所代理集团行政总裁戴志坚表示,很荣幸能够作为创始股东参与广期所的建设。这项投资符合香港交易所立足中国的战略,为香港交易所携手内地同业共同推动中国衍生品市场的发展提供了宝贵机遇。
他还表示,作为大湾区可持续金融的领导者,香港交易所希望通过支持广期所的市场化和国际化发展,与广期所共同推进大湾区绿色低碳市场的发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.